Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-26T21:55:19.763Z Has data issue: false hasContentIssue false
  • English
  • Français

Sinonasal teratocarcinosarcoma (TCS): tackle aggressively

Published online by Cambridge University Press:  14 September 2015

Siddanna Palled ,
Shekar Patil ,
Rekha Kumar  and
Shashidara Poppa Reddy
Siddanna Palled*
Affiliation:
Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
Shekar Patil
Affiliation:
Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
Rekha Kumar
Affiliation:
Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
Shashidara Poppa Reddy
Affiliation:
Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
*
Correspondence to: Dr Siddanna Palled, Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Dr M H Marigowda Road, Bengaluru 560029, Karnataka, India. Tel: +91 99 80 666727. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Sinonasal teratocarcinosarcoma (TCS) are highly aggressive and rare malignant tumours arising from the heterogeneous admixture of components of all the three germ cell layers. There are <60 cases that have been reported in the literature. In spite of aggressive therapy, the average survival is <3 years with multimodality therapy. In total, 70% of the patients who survived >1 year received regimen of combined surgery and adjuvant therapies and this suggests that aggressive therapeutic approaches may improve the treatment outcome.

Materials and methods

We are reporting a case study of sinonasal TCS treated with initial surgery followed with concurrent chemoradiotherapy using intensity-modulated radiotherapy (IMRT) technique. The concurrent chemotherapy and adjuvant chemotherapy consisted of carboplatin and etoposide.

Results

This aggressive treatment protocol of concurrent chemoradiation along with adjuvant chemotherapy is well tolerated and produced 5-year locoregional control and survival without any long-term morbidities.

Conclusion

Our treatment protocol was well tolerated and the outcome in this individual patient has been encouraging. This could justify a combined modality approach with post-operative simultaneous-integrated boost-IMRT and chemotherapy (concurrent and adjuvant) for future patient with sinonasal TCS.

Keywords

immunohistochemistryradiation therapy chemotherapysinonasal teratocarcinosarcoma
Type
Case Study
Information
Journal of Radiotherapy in Practice , Volume 14 , Issue 4 , December 2015 , pp. 438 - 441
Check for updates
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Heffner, D K, Hyams, V J. Teratocarcinosarcoma (malignant teratoma?) of the nasal cavity and paranasal sinuses a clinicopathologic study of 20 cases. Cancer 1984; 53 (10): 2140–2154.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed
2.Wang, S Y, Zhu, L, Li, S M, et al. Sinonasal teratocarcinosarcoma: a clinical, radiologic and pathologic study of 5 cases. Zhonghua Bing Li Xue Za Zhi 2007; 36 (8): 534–538 (in Chinese).Google ScholarPubMed
3.Wei, Set al. Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome. Ann Diagn Pathol 2008; 12 (6): 415–425.CrossRefGoogle ScholarPubMed
4.Takasaki, K, Sakihama, N, Takasaki, H. A case with sinonasal teratocarcinosarcoma in the nasal cavity and ethmoid sinus. Eur Arch Otorhinolaryngol 2006; 263 (6): 586–591.CrossRefGoogle ScholarPubMed
5.Nitsche, M, Hermann, R M, Christiansen, H, Berger, J, Pradier, O. Rationale for individualized therapy in Sinonasal Teratocarcinosarcoma (SNTC): case report. Onkologie 2005; 28 (12): 653–656.Google Scholar